Takezawa et al. have previously identified HER2 amplification by ISH in three of 26 EGFR mutant cases of lung adenocarcinoma, who progressed on gefitinib or erlotinib [39]. The gene discussed is ERBB2; the disease is lung adenocarcinoma.